Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: <i>post hoc</i> analysis of a randomized controlled trial

Sunao Kojima(Kumamoto University), Shigeki Moritani(Kumamoto University Hospital), Yutaka Wakasa(Kanazawa Medical Center), Hisao Ogawa(Kumamoto University Hospital), Kenichi Tsujita(Kumamoto University), Toshiya Okamoto(Diabetes Care Center), Hiroki Matsui(Nagoya University), Kunihiko Matsui(Kumamoto University), Atsuhiro Ichihara(Tokyo Women's Medical University), Hitoshi Kurumatani, Fumihiko Takeda, Kazuo Kimura(Yokohama City University Medical Center), Kouichi Kanouzawa, Kazuaki Uchiyama, Ichiro Hisatome(National Institute of Technology, Yonago College), Masako Waki(Shizuoka City Hospital), Hisao Mori, Itaru Maeda(Kumamoto University Hospital), Tomoyuki Shibuya, Masayuki Nakano, Masaki Akahata, Yoshihiko Saito(National Archives and Records Administration), Eiichi Tokutake, Yasushi Okuaki(Jikei University School of Medicine), Fumio Naganuma, Takahiro Hayashi, Naoto Yokota, Toshibumi Hogi, Yasushi Suzuki(Iwate Medical University), Yusuke Ohya(University of the Ryukyus), Nobuyuki Enomoto(The Japanese Society of Gastroenterological Surgery), Masahiro Sugawara(Nerima General Hospital), Chikako Kaneko, Takao Baba, M. Yamaki, M Yanagisawa, Masaki Miyahara, Takeshi Maki, Tetsuichi Asano, Yoshiaki Harada, Yukinobu Kobayashi, T Shimasaki, Hiroki Takeda, Hideaki Omiya
Lara D. Veeken
October 4, 2021
Cited by 18


Related Papers